Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPM.L Regulatory News (MPM)

  • There is currently no data for MPM

EPT Disclosure

25 Jan 2010 17:51

RNS Number : 0989G
Nomura Code Securities Limited
25 January 2010
 



 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS 

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

1. KEY INFORMATION

Name of exempt principal trader

Nomura Code Securities Limited

Company dealt in

Minster Pharmaceuticals Ltd

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ordinary 5p shares - ISIN:GB00B142W462

Date of dealing

25-Jan-2010

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

Interests and short positions (following dealing) in the class of relevant security 

dealt in (Note 2)

Long

Short

Number

(%)

Number )

(%)

(1) Relevant securities 

1,460,696

2.48

0

(2) Derivatives (other than options)

0

0

0

0

(3) Options and agreements to purchase/sell

0

0

0

0

Total

1,460,696

2.48

Interests and short positions in relevant securities of the company, other than the class 

dealt in (Note 2)

Class of relevant security:

Long

Short

Number

(%)

Number )

(%)

(1) Relevant securities 

0

0

0

0

(2) Derivatives (other than options)

0

0

0

0

(3) Options and agreements to purchase/sell

0

0

0

0

Total

0

0

0

0

Rights to subscribe (Note 2)

Class of relevant security:

Details

n/a

n/a

3. DEALINGS (Note 3)

(a) Purchases and sales

Purchase/sale

Number of securities

Price per unit (Note 4)

Purchase

1,437,284

5.8p

Total Purchases:

1,437,284

Total Sales:

Nil

 

(b) Derivatives transactions (other than options)

Product name, 

e.g. CFD

Long/short (Note 5)

Number of securities (Note 6)

Price per unit (Note 4)

n/a

n/a

n/a

n/a

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 6)

Exercise

price 

Type, e.g. American, European etc.

Expiry 

date

Option money

paid/received per unit (Note 4) 

n/a

n/a

n/a

n/a

n/a

n/a

n/a

(ii) Exercising

Product name, e.g. call option

Number of securities 

Exercise price per unit (Note 4)

n/a

n/a

n/a

(d) Other dealings (including new securities) (Note 3)

Nature of transaction (Note 7)

Details

Price per unit (if applicable) (Note 4)

n/a

n/a

n/a

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

Is a Supplemental Form 38.5(b) attached? (Note 8) NO

Date of disclosure

26-Jan-2010

Contact name

Niall Campbell

Telephone number

020 7776 1226

Name of offeree with which connected

Minster Pharmaceuticals plc

Nature of connection (Note 9)

Nomad and Broker

Notes

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website 

at www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMLLFEDLIIEFII
Date   Source Headline
6th Jun 20147:00 amRNSAGM Statement
23rd May 20147:00 amRNSContract wins
22nd May 20145:00 pmRNSCompletion of audit
21st May 20145:06 pmRNSAnnual General Meeting
13th May 20147:00 amRNSResults for year ended 31 December 2013
29th Apr 201411:30 amRNSNotice of results & new product launch
31st Mar 20147:00 amRNSTOTAL VOTING RIGHTS
21st Mar 20147:00 amRNSAgreement with Affiliate Window
12th Mar 20143:39 pmRNSDirector/PDMR Shareholding
11th Mar 20144:35 pmRNSBlock Admission Application
7th Mar 20147:00 amRNSNew Customer and Sector Wins
20th Jan 20147:00 amRNSPRE-CLOSE TRADING UPDATE
17th Jan 201410:17 amRNSHoldings in Company
18th Dec 20137:00 amRNSFirst Day of Dealings
5th Mar 20107:00 amRNSOffer Update
5th Mar 20107:00 amRNSCompulsory Acquisition of Minster Shares
17th Feb 20107:14 amRNSBoard Changes, Issue of Deferred Consideration
17th Feb 20107:00 amRNSOffer Update
1st Feb 201012:50 pmRNSDirectorate Change
25th Jan 20105:51 pmRNSEPT Disclosure
20th Jan 201011:59 amRNSRule 8.3- Minster Pharmaceuticals PLC
14th Jan 20104:00 pmRNSPosting of Offer Document
14th Jan 20104:00 pmRNSPosting of Offer Document
13th Jan 20102:27 pmRNSRule 8.3- Minster Pharma PLC
4th Jan 20103:11 pmRNSAcquisition of Minster Pharmaceuticals
4th Jan 20103:11 pmRNSCash Offer
20th Nov 20097:00 amRNSInterim Results
21st Sep 20097:00 amRNSDirectorate Change
15th Sep 20093:31 pmRNSChange of Registered Office
14th Sep 20097:00 amRNSTonabersat at IHS Congress
23rd Jul 20097:00 amRNSSabcomeline Patent Filing
17th Jul 200910:39 amRNSDirector/PDMR Shareholding
6th Jul 20097:00 amRNSPublication of Aura Results
30th Jun 200911:30 amRNSResult of AGM
30th Jun 20097:01 amRNSAGM Statement
30th Jun 20097:00 amRNSRajinder Kumar Appointment
2nd Jun 20095:04 pmRNSAnnual Financial Report
29th May 200910:51 amRNSGrant of Share Option to Director
29th May 200910:47 amRNSDirector/PDMR Shareholding
28th May 20097:00 amRNSPreliminary Results
20th Apr 20097:00 amRNSKarl Keegan appointed CFO
17th Apr 20097:16 amRNSDirectorate Change
11th Feb 20093:39 pmRNSHolding(s) in Company
2nd Feb 20097:00 amRNSTempus Study Results
18th Dec 200811:52 amRNSHolding(s) in Company
4th Dec 20087:00 amRNSUS Licensing Consultant
14th Nov 20087:00 amRNSInterim Results
11th Nov 20087:00 amRNSNotice of Interim Results
22nd Oct 20087:00 amRNSPositive Phase II Results
30th Jun 20087:00 amRNSSymposium at AHS Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.